CB

Aysha E. Schomburg Appointed President and Chief Executive Officer of New York Society for the Prevention of Cruelty to Children

Retrieved on: 
Jeudi, mai 9, 2024
Aisha, Society, Administration, DOE, Social Security, Join, Racism, Social, Equity, Aspen, Risk, ACF, Policy, Human services, Social services, Housing, HUD, ACS, DSS, Child, Interim, Aspen Institute, COVID-19, NYSPCC, CB, Management

NEW YORK, May 9, 2024 /PRNewswire/ -- The New York Society for the Prevention of Cruelty to Children (NYSPCC) has named Aysha E. Schomburg, J.D., as President and Chief Executive Officer, effective May 13, 2024, the NYSPCC Board of Directors announced.

Key Points: 
  • "We are delighted to welcome Aysha E. Schomburg as our new President and CEO," said Alison Hutchinson, NYSPCC Board Vice President.
  • "After an extensive search, we are confident that Aysha's expertise, collaborative spirit and extraordinary leadership will take the Society to the next level.
  • We are excited to bring in new energy to enhance our great work and look forward to Aysha forging the way forward."
  • Schomburg previously served as the Senior Administrator for Program Oversight for New York City's Administration for Children's Services (ACS).

CB Therapeutics Introduces Sustainable Retinol Production

Retrieved on: 
Jeudi, mai 9, 2024
Vitamin A, Retinol, Therapy, Biotechnology, Carbon footprint, Skin, CSO, CB, Fine chemical

Carlsbad, California--(Newsfile Corp. - May 9, 2024) - CB Therapeutics , a premier biotechnology firm specializing in precision fermentation, proudly unveils its latest breakthrough: Retinol, the quintessential solution for achieving radiant and youthful skin.

Key Points: 
  • Carlsbad, California--(Newsfile Corp. - May 9, 2024) - CB Therapeutics , a premier biotechnology firm specializing in precision fermentation, proudly unveils its latest breakthrough: Retinol, the quintessential solution for achieving radiant and youthful skin.
  • Long revered by skincare experts for its transformative properties, Retinol, a derivative of vitamin A, now enters a new era of production thanks to CB Therapeutics' cutting-edge precision fermentation and synthetic biology techniques.
  • This groundbreaking process revolutionizes Retinol production, enabling rapid, clean, and eco-friendly synthesis of both the compound itself and its derivatives.
  • Sher Butt, CEO of CB Therapeutics, expressed enthusiasm about this development, highlighting the global demand for eco-friendly alternatives in the skincare industry.

Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024: Cusatuzumab Emerges as Leading Phase II Candidate for Leukemia Treatment, Paving the Way for CD70 Therapy Evolution - ResearchAndMarkets.com

Retrieved on: 
Mardi, mai 7, 2024
Health, Oncology, Factorization of polynomials, Zhejiang University, FTD, Cancer, Investment, Nanchang University, Hospital, Survival, Partnership, Research, Leukemia, PI3K, Indication, Patient, Neoplasm, Potyvirus, CD70, MAP, Antibody, Medicine, Gene, CB, Pharmaceutical industry

The "Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.
  • Therefore, numerous pharma and biotech companies planned to develop CD70 therapy and initiated clinical trials.
  • Over the preceding decennium, the sphere of global CD70 therapy market has witnessed the development of several novel, innovative as well as advanced contenders targeting CD70.
  • The combinational study for CD70 therapy represents a novel as well as compelling frontier in the commercial CD70 therapy landscape.

CB&I Awarded Contract by TotalEnergies and OQ for Full Containment Liquefied Natural Gas Tank in Oman

Retrieved on: 
Mercredi, mai 8, 2024
USD, Natural gas, Engineering, CB&I, Port, Plant, EPC, OQ, TotalEnergies, GHG, CB

HOUSTON, May 8, 2024 /PRNewswire/ -- CB&I, a wholly owned unrestricted subsidiary of McDermott, has been awarded a significant* contract by Marsa Liquefied Natural Gas LLC, a joint venture between TotalEnergies and OQ for the engineering, procurement, construction (EPC) of a full containment concrete liquefied natural gas (LNG) storage tank, located in Oman's Port of Sohar.

Key Points: 
  • HOUSTON, May 8, 2024 /PRNewswire/ -- CB&I, a wholly owned unrestricted subsidiary of McDermott, has been awarded a significant* contract by Marsa Liquefied Natural Gas LLC, a joint venture between TotalEnergies and OQ for the engineering, procurement, construction (EPC) of a full containment concrete liquefied natural gas (LNG) storage tank, located in Oman's Port of Sohar.
  • Under the scope of the project, CB&I will provide turnkey EPC services for a 165,000m3 full containment concrete LNG storage tank and associated piping to grade.
  • Project delivery will be executed in Oman, where CB&I has been continually present since 1968, with support from CB&I's Dubai office.
  • "It supports our ambition to build storage for projects that will help provide reliable energy to markets with a reduced environmental impact.

CB Therapeutics Unveils Revolutionary Breakthroughs in Crafting Pharmaceutical-Grade Cannabinoids and Analogues

Retrieved on: 
Jeudi, mai 2, 2024
Cannabinoid, Global health, Therapy, Fermentation, Patient, Biotechnology, Safety, Carbon, CB, Fine chemical

With the recent reclassification of cannabinoids, the company hopes to revolutionize the pharmaceutical industry by offering a sustainable, standardized solution for cannabinoid therapeutics.

Key Points: 
  • With the recent reclassification of cannabinoids, the company hopes to revolutionize the pharmaceutical industry by offering a sustainable, standardized solution for cannabinoid therapeutics.
  • By harnessing the power of fermentation, CB Therapeutics ensures consistent, high-quality production of cannabinoids and their analogs, addressing the inherent variability and challenges associated with traditional cultivation methods.
  • In addition to delivering standardized and contaminant-free cannabinoids, CB Therapeutics' precision fermentation process boasts remarkable eco-friendly credentials.
  • With its cutting-edge technology and unwavering commitment to sustainability and quality, CB Therapeutics hopes to lead the charge in cannabinoid therapeutics.

CB Therapeutics Revolutionizes Color and Antioxidant Production: Precision Fermentation Sets New Standard for Cost-Efficiency and Sustainability

Retrieved on: 
Mercredi, avril 17, 2024
Research, Pharmaceutical, Sustainability, Food, Beverage, Environment, Fitness & Nutrition, Retail, Science, Biotechnology, Vitamins, Supplements, Other Science, Health, Betalain, Lutein, Carbon, Entrepreneurship, Lycopene, CSO, Nutrient, Antioxidant, Multimedia, CO2, Therapy, Fermentation, CB

CB Therapeutics (the “Company”), a frontrunner in biotechnology and precision fermentation, announces a monumental stride towards sustainability with the introduction of natural food and product colors, coupled with potent antioxidants.

Key Points: 
  • CB Therapeutics (the “Company”), a frontrunner in biotechnology and precision fermentation, announces a monumental stride towards sustainability with the introduction of natural food and product colors, coupled with potent antioxidants.
  • This innovative leap not only transforms coloration and nutrition but also sets a new benchmark for environmental responsibility in the food and industrial sectors.
  • The adoption of CB Therapeutics' innovative solutions not only elevates product quality but also reinforces a commitment to consumer well-being and environmental stewardship, emphasized Sher Ali Butt, Co-Founder and CEO of CB Therapeutics.
  • By utilizing precision fermentation, CB Therapeutics significantly reduces carbon emissions, with estimates suggesting a reduction of metric tons of CO2 annually compared to traditional color production methods.”
    CB Therapeutics is now looking to collaborate with partners in need of these sustainable colors.

Transactional demand for central bank digital currency

Retrieved on: 
Jeudi, avril 18, 2024
POS, Learning, CB, E41, Calibration, Financial regulation, Interest, ATM, Oesterreichische Nationalbank, Journal of Macroeconomics, Sensitivity, Diffusion, ITunes, Bank of Canada, P2P, Safety, NBER, Benchmarking, Prevalence, SPACE, Bernoulli, Journal of Monetary Economics, E42, Paper, European Parliamentary Research Service, Apollo, Environment, Political economy, COVID-19, Review of Economic Dynamics, Abramov, Loss, Working paper, Choice, Collection, Probability, Dowd, Castrén, Face, Noise, History, Restaurant, Journal of Political Economy, ECB, Policy, Diary, Model, Utility, Clutch (eggs), Canadian International Council, Journal of Financial Stability, JEL, Digital, Bias, Journal, Research, Classification, CBDC, SARS-CoV-2, ECMI, Credit, Odds ratio, Literature, European Central Bank, Mises Institute, Monetary economics, Section 5, Occupation, E47, Financial intermediary, Government, Supermarket, Friction, Finance, BIS, Love, Bart, The Economic Journal, Education, Risk, Section 4, Privacy, Section 3, Appetite, App Store (iOS/iPadOS), Human, DNB, International finance, Section 2, Leonhard Euler, Payment, Attention, Central bank, Consumer, EPRS, Habit, American Economic Review, Confidence interval, FCO, Central bank digital currency, Exercise, Letizia, Applied economics, Digital currency, Sale, Business cycle, Amazon, Community business development corporation, Control, Chart, Proxy, American Economic Journal, LN, Bank, Fintech, IMF, Analysis, Aggregation, Cryptocurrency
Key Points: 

    Flip AI Named One of the Most Promising AI Companies in the World by CB Insights for Bringing the ‘Holy Grail of Observability’ to All Enterprises

    Retrieved on: 
    Mercredi, avril 3, 2024
    Cloud, Prometheus, Synthetic media, Amazon, Intelligence, Lightning, SAN, CB Insights, Research, AI, CB, LLM, OpenSearch, Telemetry, Splunk, Flip, S3, Generative

    SAN FRANCISCO, April 03, 2024 (GLOBE NEWSWIRE) -- Flip AI today announced that it has been named to the CB Insights AI 100 that showcases the 100 most promising private AI companies of 2024.

    Key Points: 
    • SAN FRANCISCO, April 03, 2024 (GLOBE NEWSWIRE) -- Flip AI today announced that it has been named to the CB Insights AI 100 that showcases the 100 most promising private AI companies of 2024.
    • Flip is trusted by well-known global enterprises, including a top media and entertainment company and some of the largest financial institutions in the world.
    • “We’re honored to be named to the CB Insights AI 100 list,” said Corey Harrison, co-founder and CEO of Flip AI.
    • “When we set out to build Flip AI, we knew we were taking on a critical challenge within the industry.

    Predibase Named to the 2024 CB Insights AI 100 List

    Retrieved on: 
    Mardi, avril 2, 2024
    Internet, Data Management, Technology, Artificial Intelligence, Software, Serverless computing, Organization, GPU, Netflix, Lightning, CB Insights, Research, AI, Gemma, CB, World Bank, Collection, Zephyr, Video game

    CB Insights today named Predibase to its eighth-annual AI 100 , showcasing the 100 most promising private AI companies of 2024.

    Key Points: 
    • CB Insights today named Predibase to its eighth-annual AI 100 , showcasing the 100 most promising private AI companies of 2024.
    • “AI is taking off at lightning speed, and it’s not just big tech companies at the forefront of it,” said Deepashri Varadharajan, director of AI research at CB Insights.
    • “Our AI 100 winners – many of them early stage startups, some with very small teams – are pushing the boundaries of AI in everything from game development and battery design to agentic AI systems.”
      “We're grateful for the recognition of the CB Insights AI 100 list, further validating our view that the future is fine-tuned,” said Dev Rishi, co-founder and CEO of Predibase.
    • We also analyzed CB Insights’ exclusive interviews with software buyers and dug into Analyst Briefings submitted directly to us by startups.

    Vayu Robotics Named to the 2024 CB Insights AI 100 List

    Retrieved on: 
    Mardi, avril 2, 2024
    Robotics, Other Technology, Technology, Artificial Intelligence, Software, SOC, Lightning, CB, CB Insights, Multimedia, Research, Vayu, AI, Medical device

    Vayu Robotics , an AI company providing high-quality, low-cost robotics solutions, today announced that CB Insights named Vayu to its eighth-annual AI 100 , which showcases the 100 most promising private AI companies of 2024.

    Key Points: 
    • Vayu Robotics , an AI company providing high-quality, low-cost robotics solutions, today announced that CB Insights named Vayu to its eighth-annual AI 100 , which showcases the 100 most promising private AI companies of 2024.
    • View the full release here: https://www.businesswire.com/news/home/20240402288665/en/
      Vayu Robotics was named to the 2024 CB Insights AI 100 list in recognition for achievements in developing AI foundation models for mobility.
    • (Graphic: Business Wire)
      “Vayu Robotics is honored to be named a leader in the vertical AI space,” said Anand Gopalan, CEO and co-founder of Vayu Robotics.
    • Quick facts on the 2024 AI 100:
      68% early-stage startups building virtual worlds, autonomous factories, language models for under-represented languages, and more